

# **National Innovative Medicines Fund List**

**(Including live list of indications funded via the Innovative Medicines Fund with their commissioning criteria for use)**

**v1.24**  
**27-Feb-26**

# National Innovative Medicines Fund (IMF) List

## A. National IMF List

Notes: This list should be read in conjunction with all other available information found at: <https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/>

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
DUP1_v1.0	Dupilumab	DUP1_v1.0 - National Innovative Medicines Fund Application Form-- Initial Funding Application - Dupilumab for treating severe chronic rhinosinusitis with nasal polyps [TA1134]	<p>1. The prescribing clinician confirms the patient is an adult and has a diagnosis of severe chronic rhinosinusitis with nasal polyps.</p> <p>2. The prescribing clinician confirms dupilumab will be used in combination with intranasal corticosteroids to treat severe chronic rhinosinusitis with nasal polyps in an adult patient if</p> <ul style="list-style-type: none"> <li>the condition is not controlled well enough by systemic corticosteroids or sinus surgery, and</li> <li>they have had at least 1 sinus surgery,</li> <li>the 22-item sinonasal outcomes test (SNOT-22) score is at least 50.</li> </ul> <p>3. The prescribing clinician confirms the patient has been discussed at an appropriate MDT. The constitution of the MDT can be determined by clinical need and available resources, but should include subspecialist rhinologists, and may include either an allergy or respiratory specialist.</p> <p>4. The prescribing clinician confirms the patient will receive the licensed dose and frequency of dupilumab in line with its marketing authorisation.</p>	From 05-February-26		Yes	Agreed	No	19-May-26

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
ETR1a_v1.0	Etranacogene dezaparovec	ETR1a- Initial Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1. The prescribing clinician confirms the patient is aged 18 years or older. 2. The prescribing clinician confirms the patient has moderately severe or severe haemophilia B 3. The prescribing clinician confirms the patient has a demonstrated absence of Factor IX inhibitors and no previous history of Factor IX inhibitors. 4. The prescribing clinician confirms a pre-existing neutralising antibody titre has been performed and that the patient does not have neutralising anti-AAV5 antibodies above a titre of 1:678 (7-point assay) or 1:899 (9-point assay). 5. The prescribing clinician confirms the patient's baseline hepatic function has been assessed. 6. The prescribing clinician confirms compliance with UKHDO guideline, in particular the approval and pathway process and that treatment will be delivered by a commissioned haemophilia ATMP treatment hub. 7. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA989.	From 27-June-24		N/A	N/A	Yes	nca
ETR1b_v1.0	Etranacogene dezaparovec	ETR1b-Post Infusion Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1.The prescribing clinician confirms that one of the following applies: - The patient remained eligible for treatment and was infused with etranacogene dezaparovec - The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product - The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product - The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected) - The product was destroyed following identification of other damage to the product  Please enter the date of infusion with etranacogene dezaparovec if option 1 applies, otherwise please enter '00/00/0000': 2. The prescribing clinician confirms that etranacogene dezaparovec was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA989	From 27-June-24		N/A	N/A	Yes	nca

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access	Expected Entry into Baseline Commissioning (if
				Yes	Yes (but notice of removal served)				
EXA1a_v1.3	Exagamglogene autotemcel	EXA1a_v1.3 – National Innovative Medicines Fund Application Form – Post panel approval application – Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	<p>1. The prescribing clinician confirms that one of the following applies:</p> <p>a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR</p> <p>b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group</p> <p>2. The prescribing clinician confirms the patient has transfusion-dependent beta-thalassaemia (diagnosis confirmed by DNA technology) and is suitable for haematopoietic stem cell transplant but a human leukocyte antigen (HLA)- matched related haematopoietic stem cell donor is not available.</p> <p>3. The prescribing clinician confirms that the patient has not received a prior allogeneic or autologous haematopoietic stem cell transplant.</p> <p>4. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000) -----</p> <p>5. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA1003.</p> <p>6. The prescribing clinician confirms the required data will be collected as per the managed access agreement.</p>	From 08-August-24	N/A	N/A	Yes	nca	
EXA1b_v1.2	Exagamglogene autotemcel	EXA1b_v1.2 – National Innovative Medicines Fund Application Form – Initial Funding Application (for each cell collection) – Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	<p>1. The prescribing clinician confirms the patient remains eligible for treatment and the declarations made in FORM A 'Post panel approval application form' remain valid.</p> <p>2. The prescribing clinician confirms that one of the following applies</p> <p>2a. The prescribing clinician confirms this is the patients first mobilisation cycle* OR</p> <p>2b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR</p> <p>2c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR</p> <p>2d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR</p> <p>2e. The prescribing clinician confirms this is the patients fifth mobilisation cycle*</p> <p>*One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that may occur from Day 5 to Day 7 (inclusive).</p>	From 08-August-24	N/A	N/A	Yes	nca	
EXA1c_v1.0	Exagamglogene autotemcel	EXA1c_v1.0 – National Innovative Medicines Fund Application Form – Funding Application (treatment) – Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	<p>1. The prescribing clinician confirms that one of the following applies:</p> <p>a. The patient remained eligible for treatment and was infused with exagamglogene autotemcel.</p> <p>b. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product.</p> <p>c. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product.</p> <p>d. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected).</p> <p>e. The product was destroyed following identification of other damage to the product.</p> <p>2. If option 1a applies, The prescribing clinician confirms that Exagamglogene autotemcel was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA 1D4016 and please enter the date of infusion with Exagamglogene autotemcel, otherwise please enter '00/00/0000'.</p>	From 04-November-25	N/A	N/A	Yes	nca	

# National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
EXA2a_v1.4	Exagamlogene autotemcel	EXA2a_v1.4-National Innovative Medicines Fund Application Form – Post panel approval application – Exagamlogene autotemcel for treating sickle cell disease [TA1044] where the following criteria have been met:	<p>1. To note, a separate Blueteq form should be submitted for use of plerixafor</p> <p>1a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR</p> <p>1b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group.</p> <p>2. The prescribing clinician confirms the patient has sickle cell disease and has recurrent vaso-occlusive crises (VOCs) defined as at least 2 VOC's per year during the 2 previous years.</p> <p>To note: In the SmPC: Patients were eligible for the study if they had a history of at least 2 severe vaso-occlusive crisis events per year in the 2 years prior to screening, which were defined as:  <ul style="list-style-type: none"> <li>•an acute pain event</li> <li>•acute chest syndrome</li> <li>•pruritus lasting at least 2 hours</li> <li>•splenic sequestration.</li> </ul> </p> <p>3. The prescribing clinician confirms the patient:                      a. has <math>\beta\text{S}/\beta\text{S}</math>, <math>\beta\text{S}/\beta^+</math> or <math>\beta\text{S}/\beta\text{O}</math> genotype,                      b. is suitable for haematopoietic stem cell transplant,                      c. and for whom a human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is not available.</p> <p>4. The prescribing clinician confirms that the patient has not received a prior allogeneic or autologous successful haematopoietic stem cell transplant.</p> <p>5. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000)</p> <p>6. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA1044</p> <p>7. The prescribing clinician confirms the required data will be collected as per the managed access agreement</p>	From 31-January-25	N/A	N/A	Yes	nca	
EXA2b_v1.2	Exagamlogene autotemcel	EXA2b_v1.2-National Innovative Medicines Fund Application Form – Initial Funding Application (for each cell collection) – Exagamlogene autotemcel for treating sickle cell disease [TA1044] where the following criteria have been met:	<p>1. The prescribing clinician confirms the patient remains eligible for treatment and the declarations made in FORM A 'Post panel approval application form' remain valid.</p> <p>2. To note, a separate Blueteq form should be submitted for use of plerixafor</p> <p>Please choose one of the following:                      1a. The prescribing clinician confirms this is the patients first mobilisation cycle* OR                      1b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR                      1c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR                      1d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR                      1e. The prescribing clinician confirms this is the patients fifth mobilisation cycle* OR                      1f. The prescribing clinician confirms this is the patients sixth mobilisation cycle*                      * One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that occur from Day 1 to Day 3 (inclusive).</p>	From 31-January-25	N/A	N/A	Yes	nca	
EXA2c_v1.0	Exagamlogene autotemcel	EXA2c_v1.0-National Innovative Medicines Fund Application Form – Funding Application (treatment) – Exagamlogene autotemcel for treating sickle cell disease [TA1044] where the following criteria have been met:	<p>1. The prescribing clinician confirms that one of the following applies:                      a. The patient remained eligible for treatment and was infused with exagamlogene autotemcel.                      b. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product.                      c. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product.                      d. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected).                      e. The product was destroyed following identification of other damage to the product.</p> <p>2. If option 1a applies, I confirm that Exagamlogene autotemcel was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA ID40161044 and please enter the date of infusion with Exagamlogene autotemcel, otherwise please enter '00/00/0000'.</p>	From 04-November-25	N/A	N/A	Yes	nca	

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
NAT1a_v1.0	Natalizumab	NAT1a_v1.0_National Innovative Medicines Fund Application Form– Initial Funding Application – Natalizumab (subcutaneous originator and intravenous biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [TA1126] where the following criteria have been met:	1.The prescribing clinician confirms the patient has a diagnosis of highly active relapsing-remitting multiple sclerosis (RRMS). 2.The prescribing clinician confirms the patient has not responded to a full and adequate course of at least 1 disease-modifying therapy. 3.The prescribing clinician confirms the characteristics of the patient and the activity of their MS mean that cladribine is not suitable. 4.The prescribing clinician confirms the patient's EDSS score has been recorded in the patient's notes. Please select score: • 0-4.0 • 4.5-5.5 • 6 • 6.5 • 7+ 5.The prescribing clinician confirms the stopping criteria have been explained and agreed with the patient and/or carer before the treatment is started. 6.The prescribing clinician confirms the patient will be reassessed and treatment will be stopped if there has not been an adequate response. 7.The prescribing clinician confirms the licensed dose and frequency of natalizumab will not be exceeded* * If using extended interval dosing as outlined in the SmPC (e.g. 6 weekly) caution is required because the efficacy of extended interval dosing has not been established and the associated benefit risk balance is currently unknown. Use should be approved via Trust Drugs and Therapeutic Committee or equivalent and reflected in local practice guidance. 8.The prescribing clinician confirms the use of natalizumab has been discussed at a multi-disciplinary team (MDT) meeting.	From 28-Jan-26	Yes	Agreed	No	28-Apr-26	
NAT1b_v1.0	Natalizumab	NAT1b_v1.0_National Innovative Medicines Fund Application Form– Continuation Funding Application – Natalizumab (subcutaneous originator and intravenous biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [TA1126] where the following criteria have been met:	1.The prescribing clinician confirms the patient remains eligible for natalizumab in accordance with NICE ID [TA1126] 2.The prescribing clinician confirms the patient has been assessed for therapeutic benefit and risk, and the treatment remains clinically appropriate to continue. 3.The prescribing clinician confirms the patient's EDSS score has been recorded in the patient's notes. Please select score: • 0-4.0 • 4.5-5.5 • 6 • 6.5 • 7+	From 28-Jan-26	Yes	Agreed	No	28-Apr-26	

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
OBI3a_v1.0	Obinutuzumab	OBI3a_v1.0_National Innovative Medicines Fund Application Form– Initial Funding Application – Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [TA11478] where the following criteria have been met:	1.The prescribing clinician the patient is 18 years and over. 2.The prescribing clinician the patient has a diagnosis of class III or IV (with or without concomitant class V) lupus nephritis 3.The prescribing clinician the patient will receive the licensed dose and frequency of obinutuzumab in line with its marketing authorisation. 4.The prescribing clinician that this patient has been discussed with a relevant specialist MDT (which includes a renal specialist) and it has been agreed that obinutuzumab is the most appropriate therapy.	From 22-Jan-26	Yes	Agreed	No	22-Apr-26	
OBI3b_v1.0	Obinutuzumab	OBI3b_v1.0_National Innovative Medicines Fund Application Form– Continuation Funding Application – Obinutuzumab with mycophenolate mofetil for treating lupus nephritis [TA11478] where the following criteria	1.The prescribing clinician confirms the patient has had an adequate response to treatment with Obinutuzumab after initiation of therapy and treatment will only be continued if an adequate response is assessed and maintained every 12 months.	From 22-Jan-26	Yes	Agreed	No	22-Apr-26	

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
PEG1a_v1.0	Pegzilarginase	PEG1a_v1.0 - National Innovative Medicines Fund Application Form - Initial Funding Application - Pegzilarginase for treating arginase-1 deficiency [ID4029]	1.The prescribing clinician confirms the patient is aged 2 years and over. 2.The prescribing clinician confirms patient has a diagnosis of arginase-1 deficiency (also called hyperargininaemia). 3.The prescribing clinician confirms that the patient has been discussed within a minuted inherited metabolic disorders MDT, and it has been agreed that pegzilarginase is the most appropriate therapy. 4.The prescribing clinician confirms the patient will receive the licensed dose and frequency of pegzilarginase in line with its marketing authorisation.	Yes	Yes (but notice of removal served)	Yes	Agreed	No	Tbc

## National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use			Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access	Expected Entry into Baseline Commissioning (if
				Yes	Yes (but notice of removal served)				
VUT1a_10	Vutrisiran	VUT1a – Initial Funding Application – Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy [TA1115]	1. The prescribing clinician confirms the patient is 18 years and over. 2. The prescribing clinician confirms the patient has a diagnosis of wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) based on a tissue biopsy showing ATTR amyloid or fulfilment of the non-biopsy diagnostic criteria for ATTR-CM. 3. The prescribing clinician confirms the patient will receive the licensed dose and frequency of vutrisiran in line with its marketing authorisation.	From 10-Dec-25		Yes	Agreed	No	10-Mar-26
VUT1b_10	Vutrisiran	VUT1b – Continuation Funding Application – Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy [TA1115]	1. The prescribing clinician confirms the patient has had an adequate response to treatment with vutrisiran after initiation of therapy and treatment will only be continued if an adequate response is assessed and maintained every 12 months.	From 10-Dec-25		Yes	Agreed	No	10-Mar-26

## National Innovative Medicines Fund (IMF) List

### B. IMF drug moved into routine commissioning

	IMF drug moved into routine commissioning				
	Form code	Drug name	Indication	Start date of IMF funding	Date of routine commissioning
	BUL1_v1.0	Bulevirtide	Bulevirtide for treating chronic hepatitis D (TA896)	07/06/2023	05/09/2023
	SEC1_v1.0	Secukinumab	Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)	27/10/2023	06/03/2024
	SEB1_v1.0	Sebelipase alfa	Sebelipase alfa for treating Wolman disease (HST30)	27/11/2023	09/04/2024
	BEL1_v1.0	Belumosudil	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)	21/12/2023	07/05/2024
	VOX1a_v1.0	Voxelotor	Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)	03/05/2024	12/07/2024
	IPT1_v1.0	Iptacopan	Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)	04/09/2024	03/12/2024
	ELAF1_v1.0	Elaftibranor	Elaftibranor for treating primary biliary cholangitis (TA1016)	22/10/2024	12/02/2025
	TAF1a_v1.0	Tafamidis	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)	13/05/2024	19/07/2024
	CRO1_v1.0	Crovalimab	Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)	20/11/2024	20/12/2024
	UBL1_v1.0	Ublituximab	Ublituximab for treating relapsing multiple sclerosis (TA1025)	29/11/2024	17/01/2025
	FEN1_v1.0	Fenfluramine	Fenfluramine for treating seizures associated with Lennox-Gastaut syndrome in people 2 years and over (TA1050)	20/02/2025	24/06/2025
	STS1_v1.0	Sodium thiosulfate	Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)	26/02/2025	22/04/2025
	RUX3_v1.0	Ruxolitinib	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)	21/03/2025	14/07/2025
	LEN1_v1.0	Leniolisib	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)	13/03/2025	22/07/2025
	MAR1_v1.0	Marstacimab	Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)	23/06/2025	22/09/2025
	IDEB1_v1.0	Idebenone	Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over (TA1093)	10/09/2025	26/11/2025
	BENR1_v1.0	Benralizumab	Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)	14/08/2025	02/12/2025
	GAR1_v1.0	Garadacimab	Garadacimab for preventing recurrent attacks of hereditary angioedema (HAE) in people 12 years and over (TA1101)	23/10/2025	06/01/2026
	CBTG1_v1.0	Cabotegravir	Cabotegravir for preventing HIV-1 in adults and young people (TA1106)	05/11/2025	03/02/2026

# National Innovative Medicines Fund (IMF) List

Version Control			
Version No.	Date published	Author(s)	Revision summary
0.1	n/a	D Dwyer	Initial draft of new IMF list, based on pre-existing national IMF list but updated for changes to the IMF, for review.
1.0	03/07/2024	S Patel; R Gowa; P Ryan; S Ahmed	Final version of new IMF list
1.1	19/08/2024	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 2 drugs/indications removed from the list
1.2	06/09/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.3	22/10/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.4	20/11/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.5	06/12/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drugs/indications removed from the list
1.6	20/12/2024	R Gowa; S Ahmed	1 drug/indication recommended for the IMF
1.7	23/12/2024	R Gowa; S Ahmed	1 drug/indication removed from the list
1.8	31/01/2025	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 1 drugs/indications removed from the list
1.9	20/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.10	27/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.11	21/03/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.12	27/03/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.13	24/06/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 2 drugs/indications removed from the list
1.14	16/07/2025	S Mcaleer;S Ahmed	2 drugs/indications removed from the list, Added List : B. IMF drug moved into routine commissioning
1.15	14/08/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.16	11/09/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.17	23/10/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drug/indication removed from the list
1.18	05/11/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drug/2 indications forms updated
1.19	03/12/2025	S Mcaleer;S Ahmed	2 drugs/indications removed from the list
1.20	06/01/2026	S Mcaleer;S Ahmed	1drug/indication removed from the list
1.21	15/01/2026	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.22	28/01/2026	S Mcaleer;S Ahmed	2 drugs/indications recommended for routine commissioning, receiving IMF interim funding
1.23	05/02/2026	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drug/indication removed from the list
1.24	19/02/2026	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding

## National Innovative Medicines Fund (IMF) List

Changes to recent versions	General or criteria changed	Summary of changes
	<b>Changes to version 1.0</b>	
	ETR1a_v1.0, ETR1b_v1.0	Recommended for the IMF
	VOX1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	TAF1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.1</b>	
	EXA1a_v1.0, EXA1b_v1.0	Recommended for the IMF
	VOX1a_v1.0, TAF1a_v1.0	Removed from the list
	<b>Changes to version 1.2</b>	
	IPT1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.3</b>	
	ELAF1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	EXA1a_v1.0, EXA1b_v1.0	Updated EXA1a questions Q4 & Q5; EXA1b Question 2&3 combined
	<b>Changes to version 1.4</b>	
	CRO1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	ETR1a_v1.0, ETR1b_v1.0, EXA1a_v1.0, EXA1b_v1.0, ELAF1_v1.0 and IPT1_v1.0	Updated IDs
	<b>Changes to version 1.5</b>	
	UBL1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	IPT1_v1.0	Removed from the list
	<b>Changes to version 1.6</b>	
	CRO1_v1.1	Updated CRO1 question 2 & added a new question.
	<b>Changes to version 1.7</b>	
	CRO1_v1.1	Removed from the list
	<b>Changes to version 1.8</b>	
	EXA2a_v1.0, EXA2b_v1.0	Recommended for the IMF
	UBL1_v1.0	Removed from the list
	<b>Changes to version 1.9</b>	
	FEN1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.10</b>	
	STS1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	ELAF1_v1.0	1 drugs/indications removed from the list
	<b>Changes to version 1.11</b>	
	LEN11a_v1.0 and LEN11b_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.12</b>	
	RUX3_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.13</b>	
	MAR1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.14</b>	
	RUX3_v1.0	Removed from the list
	LEN11a_v1.0 and LEN11b_v1.0	Removed from the list
	<b>Changes to version 1.15</b>	
	BENR1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.16</b>	
	IDEB1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.17</b>	
	GAR1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	MAR1_v1.0	Removed from the list
	<b>Changes to version 1.18</b>	
	CBTG1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	EXA1a_v1.3, EXA1b_v1.2	Removed Q5 from EXA1a ; Updated both Q1 & Q2 in EXA1b
	EXA2a_v1.4, EXA2b_v1.2	Updated Question 5 in EXA2a; Updated both Q1 & Q2 in EXA2b
	EXA1c_v1.0, EXA2c_v1.0	Added new form
	<b>Changes to version 1.19</b>	
	IDEB1_v1.0	Removed from the list
	BENR1_v1.0	Removed from the list
	<b>Changes to version 1.20</b>	
	GAR1_v1.0	Removed from the list
	<b>Changes to version 1.21</b>	
	VUT1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	VUT1b_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.22</b>	
	NAT1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	NAT1b_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	OBI3a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	OBI3b_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	<b>Changes to version 1.23</b>	
	DUP1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
	CBTG1_v1.0	Removed from the list
	<b>Changes to version 1.24</b>	
	PEG1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding